BioCentury
ARTICLE | Company News

Novo Nordisk, J&J, Innate Pharma deal

June 15, 2015 7:00 AM UTC

Johnson & Johnson’s Janssen Biotech Inc. unit received an exclusive, worldwide license from Novo Nordisk to develop and commercialize anti-NKG2D ( NN8555) for autoimmune indications. Last year, Novo ...